DDInter1642 DDInter1526
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
Procarbazine {u} (Compound) resembles {v} (Compound) Atenolol
Procarbazine {u} (Compound) treats {v} (Disease) hematologic cancer
Procarbazine {u} (Compound) binds {v} (Gene) CYP1B1
Procarbazine {u} (Compound) upregulates {v} (Gene) MOK
Procarbazine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Procarbazine {u} (Compound) downregulates {v} (Gene) DLD
Procarbazine {u} (Compound) causes {v} (Side Effect) Headache
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Procarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guanadrel
Procarbazine (Compound) resembles Atenolol (Compound)
Procarbazine (Compound) treats hematologic cancer (Disease)
Procarbazine (Compound) binds CYP1B1 (Gene)
Procarbazine (Compound) upregulates MOK (Gene)
Procarbazine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Procarbazine (Compound) downregulates DLD (Gene)
Procarbazine (Compound) causes Headache (Side Effect)
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel